In vivo最新文献

{"title":"IgG4-related Disease of the Retroperitoneum Mimics Malignancy: A Case Report and Literature Review.","authors":"Gaia Cicioni, Immacolata Iannone, Daniele Crocetti, Cristina DE Padua, Alessandro Coppola, Luigi Petramala, Paolo Sapienza, Claudio Letizia","doi":"10.21873/invivo.14011","DOIUrl":"10.21873/invivo.14011","url":null,"abstract":"<p><strong>Background/aim: </strong>Immunoglobulin G4-related disease (IgG4-RD) is a systemic, immune-mediated condition characterized by fibroinflammatory lesions affecting multiple organs. When localized in the retroperitoneum, it may mimic malignancy and often leads to surgical intervention. We report the case of a 21-year-old male with retroperitoneal IgG4-RD and review the relevant literature, emphasizing the diagnostic challenges and importance of differential diagnosis.</p><p><strong>Patients and methods: </strong>A case report of a 21-year-old man with retroperitoneal IgG4-RD is presented. A literature review was conducted <i>via</i> Scopus, Embase, and Medline through December 2024, selecting studies with immunohistochemically confirmed retroperitoneal IgG4-RD. Data were independently extracted and analyzed using SPSS software.</p><p><strong>Results: </strong>Of 74 articles retrieved, 22 met the inclusion criteria, totaling 23 patients including our case. The mean age was 62 years, with a male predominance (65%). The left ureter was most commonly involved (52%). Frequent symptoms included localized abdominal pain (61%) and hydronephrosis (96%). Imaging often suggested malignancy, leading 74% of patients to undergo surgery. Histopathology confirmed IgG4-RD in all cases, though only 30% showed IgG4 immunohistochemical positivity.</p><p><strong>Conclusion: </strong>Retroperitoneal IgG4-RD closely mimics malignancy, posing significant diagnostic challenges. Elevated serum IgG4 levels and tissue biopsy are critical for accurate diagnosis. IgG4-RD should be considered in patients with unexplained retroperitoneal masses to avoid unnecessary surgery and ensure appropriate treatment.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2154-2164"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered Levels of <i>miRNA-1290</i> and <i>lncRNA-H19</i> in Exosomes of Patients Recently Diagnosed With Acute Lymphoblastic Leukemia.","authors":"Daniel Zavala-Reyes, Juan Manuel Vargas-Morales, Rosa Del Carmen Milán-Segovia, Miguel Ernesto Martínez-Leija, Edith Elena Uresti-Rivera, Oswaldo Hernández-González, Rosana Pelayo-Camacho, Diana Patricia Portales-Pérez","doi":"10.21873/invivo.13993","DOIUrl":"10.21873/invivo.13993","url":null,"abstract":"<p><strong>Background/aim: </strong>Acute lymphoblastic leukemia (ALL) is a common childhood cancer characterized by high levels of blasts in the bone marrow, and it is influenced by genetic and microenvironmental factors. Genetic variants of the enzyme arylamine <i>N</i>-acetyltransferases 1 (NAT1), regulated by microRNA (miRNA) and long noncoding RNA (lncRNA), have been associated with predisposition to ALL. This study analyzed the characteristics of exosomes from patients newly diagnosed with ALL, patients already under ALL treatment, and healthy controls.</p><p><strong>Materials and methods: </strong>Exosomes were isolated from the serum of patients with ALL (n=13) and healthy children (n=18). The size, zeta potential, immunophenotype, and expression of <i>miR-1290, miR-26b, miR-126</i>, and <i>lncRNA-H19</i> from exosomes were determined using a ZetaSizer Nano ZS instrument, flow cytometry and reverse transcription polymerase chain reaction, respectively.</p><p><strong>Results: </strong>Exosomes from patients with ALL were larger and exhibited lower complexity compared with those from controls, with reduced levels of CD81⁺CD63⁺CD9⁺ exosomes, particularly in newly diagnosed cases. A decrease in CD19 expression and an increase in CD34 expression were observed in exosomes from patients with ALL compared with controls, while CD10 was present in both groups. Additionally, exosomes from patients with ALL, particularly those with the pro-B (B1) subtype, showed significantly increased expression of <i>miR-1290</i> and <i>lncRNA-H19</i> compared with controls.</p><p><strong>Conclusion: </strong>These findings suggest that exosomes not only reflect the pathophysiology of ALL but may also play a crucial role in its development and progression. Furthermore, exosomes and their non-coding RNA content emerge as potential biomarkers for ALL diagnosis and prognosis, opening avenues for future research to explore their functional role and therapeutic potential.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1941-1964"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of the Geriatric Nutritional Risk Index in the Evaluation of Outcomes of Patients After Radical Gastrectomy.","authors":"Mie Tanabe, Toru Aoyama, Itaru Hashimoto, Yuta Nakayama, Junya Morita, Kyohei Kanematsu, Shinsuke Nagasawa, Yukio Maezawa, Takanobu Yamada, Takashi Ogata, Aya Saito, Takashi Oshima","doi":"10.21873/invivo.14023","DOIUrl":"10.21873/invivo.14023","url":null,"abstract":"<p><strong>Background/aim: </strong>The clinical evaluation of the GNRI in nutritional status management has been reported in several malignancies. This study aimed to investigate the relationship between the GNRI and clinical outcomes in postoperative patients who underwent radical gastrectomy.</p><p><strong>Patients and methods: </strong>Clinical data of 940 gastric cancer patients who underwent radical gastrectomy at Kanagawa Cancer Center from 2013 to 2020 were retrospectively collected and divided into a high-GNRI group (≥98) and a low-GNRI group (<98) according to the GNRI. The association between the GNRI and overall survival (OS) and recurrence-free survival (RFS) was investigated.</p><p><strong>Results: </strong>The respective 3- and 5-year OS rates were 92.0% and 86.3% in the high-GNRI group and 82.4% and 73.2% in the low-GNRI group (<i>p</i><0.001). A multivariate analysis showed that the GNRI was an independent predictor of the OS and RFS.</p><p><strong>Conclusion: </strong>GNRI is an objective, noninvasive, and easily accessible prognostic biomarker for gastric cancer patients. Patient stratification using the GNRI and preoperative nutritional interventions may improve prognosis.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2277-2285"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PLLA Coating of Lyophilized Human Bone Allograft for Long-term Release of Antibiotics.","authors":"Mike Barbeck, Jiawei Zhang, Sanja Stojanovic, Milena Radenkovic, Stevo Najman, Anne Foth, Ole Jung, Florian Beuer, Xin Xiong","doi":"10.21873/invivo.13987","DOIUrl":"10.21873/invivo.13987","url":null,"abstract":"<p><strong>Background/aim: </strong>Mineralized allogeneic bone substitutes are ideal biomaterials for bone regeneration in surgeries. Moreover, they are also suitable for releasing antibiotics, delivering initial concentrations many times higher than the minimal inhibitory concentration for relevant bacterial strains, without delaying bone formation. In the present study, the potential of sustained-release long-term antibiotic delivery using allografts was investigated. A broad spectrum of antibiotics, including gentamicin, vancomycin, rifampicin, and clindamycin, was incorporated into the bone blocks using a poly-L-lactic acid (PLLA) polymer coating.</p><p><strong>Materials and methods: </strong>An <i>in-vivo</i> model of implantation within the rabbit tibia plateau was used to track the sustained release of single/combined antibiotics for up to 120 days. Bony integration and tissue responses to the PLLA-coated antibiotic-delivery systems were analyzed at 4 months post implantation using histopathological analysis.</p><p><strong>Results: </strong>The variant loaded with both vancomycin and rifampicin demonstrated the highest activity against methicillin-sensitive <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>. Histopathological analysis revealed that the tissue responses to the coated allogeneic bone substitutes were comparable in all study groups, with no observable histopathological differences. The coated bone blocks induced a strong foreign-body reaction, including high numbers of multinucleated giant cells and other immune cells but no material-associated bone growth.</p><p><strong>Conclusion: </strong>Based on these results, future optimization can focus on selecting more efficient release of antibiotics and increasing the encapsulated concentration to sustain antibiotic release over 4 months, thereby improving the bacteriostatic effect <i>in vivo</i>. Furthermore, biocompatibility and osteoconductivity must be improved.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1879-1890"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events.","authors":"Hirotaka Suto","doi":"10.21873/invivo.13983","DOIUrl":"10.21873/invivo.13983","url":null,"abstract":"<p><p>Immune-related adverse events (irAEs) are excessive immune responses resembling autoimmune diseases, induced by immune checkpoint inhibitors (ICIs), and can affect organs throughout the body. In contrast to AEs associated with conventional cytotoxic anticancer agents, irAEs may persist or recur after treatment discontinuation. The risk of irAEs recurrence is thought to vary depending on the type and severity of the initial irAE, while the response rate depends on the type and sequence of ICIs re-administered. Therefore, the decision to resume ICI therapy depends on the type and severity of prior irAEs, as well as the anticipated benefits and risks of resumption. This review focuses on the risks and benefits of resuming ICI therapy after each irAE and summarizes the procedure for its resumption.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1833-1839"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Predictors in Obstructive Colorectal Cancer: A Combined Clinical, Inflammatory, and Histopathological Approach.","authors":"Ahmet Tarik Harmantepe, Adem Şentürk","doi":"10.21873/invivo.14041","DOIUrl":"10.21873/invivo.14041","url":null,"abstract":"<p><strong>Background/aim: </strong>Obstructive colorectal cancer (oCRC) accounts for a significant proportion of colorectal malignancies and is associated with poor prognosis and higher perioperative morbidity. Inflammation-based biomarkers have emerged as potential predictors of survival in various cancers. However, their prognostic role in oCRC remains unclear.</p><p><strong>Patients and methods: </strong>This retrospective study included patients who underwent surgery for histopathologically confirmed oCRC at Sakarya University Training and Research Hospital between January 2015 and February 2024. Preoperative systemic inflammatory markers-C-reactive protein-to-albumin ratio (CAR), lymphocyte-to-C-reactive protein ratio (LCR), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammatory index (SII), and HALP score-were analyzed. Overall survival was recorded, and statistical analyses were performed.</p><p><strong>Results: </strong>Among the inflammatory markers, CAR, LCR, and PNI were significantly associated with overall survival at 1, 3, and 5 years (<i>p</i> <0.05). LCR demonstrated the highest sensitivity and specificity in predicting mortality. Patients with higher CAR and lower PNI values had significantly poorer outcomes.</p><p><strong>Conclusion: </strong>Preoperative systemic inflammatory markers, particularly LCR, CAR, and PNI, are valuable prognostic indicators in patients with oCRC. These easily obtainable markers may help guide clinical decision-making and improve individualized patient management.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2419-2428"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors.","authors":"Manabu Watanabe, Hiroyuki Tsuchie, Hiroyuki Nagasawa, Michio Hongo, Yuji Kasukawa, Daisuke Kudo, Fumihito Kasama, Keita Oya, Takashi Kawaragi, Naohisa Miyakoshi","doi":"10.21873/invivo.13995","DOIUrl":"10.21873/invivo.13995","url":null,"abstract":"<p><strong>Background/aim: </strong>Breast cancer frequently metastasizes to the bone, reducing quality of life and survival. Zoledronic acid (ZA), is used to treat bone metastasis; however, differences in efficacy depending on the timing of administration are not clear. This study investigated the effects of different timing of ZA administration in a mouse model of breast cancer bone metastasis.</p><p><strong>Materials and methods: </strong>E0771 cells (1.0×10⁵ cells/10 μl) were injected into the femur of C57BL/6 mice to create a local bone metastasis model. The groups that started ZA administration one week before, at the same time as, one week after, and two weeks after tumor-cell administration were designated as the -1w, 0w, 1w, and 2w groups, respectively. A fifth group that did not receive ZA treatment was created as a control. ZA was administered at a dose of 100 μg/kg, and the same dose was administered once a week from the start of administration. The animals were sacrificed two and five weeks after tumor-cell administration. We evaluated body weight at the time of tumor-cell administration and sacrifice, and after sacrifice, the weight of the affected thigh, tumor volume, and bone destruction rate were determined using micro-computed tomography. Tumor necrosis and tumor growth were measured using histological immunostaining.</p><p><strong>Results: </strong>Five weeks after tumor-cell administration, bone destruction rate was significantly lower in all groups compared to the control group (<i>p</i><0.05). Additionally, the -1w group exhibited a significantly lower bone destruction rate than 1w and 2w groups (<i>p</i><0.05). There were no significant differences in tumor necrosis, but tumor growth was significantly lower in the -1w and 0w groups (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>The earlier ZA was administered, the more strongly it suppressed bone destruction and tumor cell proliferation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1984-1991"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Cardiovascular Changes Following Cerebral Ischemia in a Non-human Primate Thromboembolic Stroke Model.","authors":"Tetsuya Yoshikawa, Yuki Akiyoshi, Tsuyoshi Uchino, Hiroaki Kawaguchi","doi":"10.21873/invivo.13996","DOIUrl":"10.21873/invivo.13996","url":null,"abstract":"<p><strong>Background/aim: </strong>Acute cardiovascular changes following cerebral ischemia are significant contributors to stroke-related mortality, yet their mechanisms remain poorly understood. This study investigated cardiovascular responses in a cynomolgus monkey thromboembolic stroke model.</p><p><strong>Materials and methods: </strong>A thromboembolic stroke model was induced in eight male animals (aged 4 to 6 years) by occlusion of the left middle cerebral artery with an autologous blood clod. Arterial blood pressure, heart rate, respiratory rate, and body temperature were continuously monitored in conscious, free-moving animals for 24 h post-embolization using a telemetry system.</p><p><strong>Results: </strong>Blood pressure, heart rate, and respiratory rate significantly increased following embolization and these increases persisted for 24 h. Circadian rhythm disruption was suggested by elevated nighttime respiratory rate and body temperature. Three moribund animals exhibited higher blood pressure, heart rate, and respiratory rate compared to five non-moribund animals, along with a drop in body temperature in the hours before death. Electrocardiographic analysis revealed no major abnormalities in non-moribund animals, but the moribund animals showed arrhythmias and ST-segment elevation before death.</p><p><strong>Conclusion: </strong>These cardiovascular changes closely resemble those observed in stroke-heart syndrome in humans, highlighting the relevance of this non-human primate model in studying acute cardiovascular complications following cerebral ischemia. This model could be applied in the development of therapies for managing post-stroke cardiovascular events.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1992-2003"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Hydrogen Therapy in Rheumatoid Arthritis: A Case Report on the Amelioration of Methotrexate-induced Myelosuppression and Immune Modulation.","authors":"Ting-Hao Tu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.14014","DOIUrl":"10.21873/invivo.14014","url":null,"abstract":"<p><strong>Background/aim: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease with systemic manifestations. Methotrexate (MTX) remains a cornerstone of RA treatment, offering significant therapeutic benefits; however, it is also associated with adverse effects, particularly myelosuppression. Molecular hydrogen, recognized for its anti-inflammatory and antioxidant properties, has demonstrated potential in mitigating oxidative stress and modulating immune responses in RA. This study aimed to evaluate the efficacy of molecular hydrogen therapy in alleviating MTX-induced myelosuppression while preserving its immunoregulatory effects in a patient with RA.</p><p><strong>Case report: </strong>We present the case of a 66-year-old Taiwanese female diagnosed with RA according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria. The patient presented to the emergency department on August 30, 2024, with oral ulcers, sore throat, weakness, and diarrhea. Clinical assessment revealed hypotension, tachycardia, pancytopenia, hepatic insufficiency, and acute kidney injury. Outpatient medications were discontinued, and molecular hydrogen therapy was initiated. The patient exhibited marked clinical improvement, with normalization of laboratory parameters. Flow cytometry analysis demonstrated a progressive increase in the percentages of PD-1+ subsets of Th and Tc cells, as well as memory and activated regulatory T (Treg) cells. In contrast, B regulatory (Breg) cell levels remained unchanged. No adverse events were observed during the course of hydrogen therapy.</p><p><strong>Conclusion: </strong>This is the first case report to highlight severe MTX-induced myelosuppression in an RA patient and to demonstrate the potential of molecular hydrogen therapy in modulating immune markers.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2186-2195"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Older Patients Undergoing Surgery for Esophageal Squamous Cell Carcinoma.","authors":"Takuya Iguchi, Satoshi Nakamura, Masato Kitazawa, Yuta Yamamoto, Satoru Miyazaki, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Ryosuke Aoki, Park Yonghan, Yuji Soejima","doi":"10.21873/invivo.14024","DOIUrl":"10.21873/invivo.14024","url":null,"abstract":"<p><strong>Background/aim: </strong>Esophageal cancer is a leading cause of death among males worldwide, including Japan, where squamous cell carcinoma is the most common type. Treatment decisions can be complicated, especially for older patients undergoing esophagectomy, which, while effective, is invasive and incurs significant risks.</p><p><strong>Patients and methods: </strong>A retrospective review of 126 consecutive patients with esophageal squamous cell carcinoma (ESCC) who underwent open or thoracoscopic esophagectomy between January 2010 and April 2023 was conducted. Older patients aged ≥75 years (n=24) were compared with non-older patients aged <75 years (n=102).</p><p><strong>Results: </strong>Both estimated Glomerular Filtration Rate (eGFR) and albumin levels were notably lower in older patients with a more extensive medical history and higher American Society of Anesthesiologists Physical Status scores. However, there were no differences in sex, Body Mass Index, or pathological stage. Both groups showed similar characteristics in terms of the esophagectomy approach, field dissection, preoperative treatment, operation duration, bleeding, postoperative complications, and hospital stay. No differences were observed between non-older and older groups regarding overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS) (5-year OS: 63.4% <i>vs</i>. 29.2%, respectively, <i>p</i>=0.119; 5-year RFS: 48.6% <i>vs</i>. 33.9%, respectively, <i>p</i>=0.612; 5-year DSS: 73.2% and 46.2%, respectively, <i>p</i>=0.978). Additionally, multivariate survival analysis indicated that pathological N stage [hazard ratio (HR)=2.13; 95% confidence interval (CI)=1.10-4.12; <i>p</i>=0.025] and pathological T stage (HR=2.16; 95%CI=1.13-4.15; <i>p</i>=0.021) were independent prognostic factors for OS. However, age was not a prognostic factor.</p><p><strong>Conclusion: </strong>Esophagectomy for patients aged 75 years or older provides comparable long-term outcomes without increasing postoperative complications compared with patients younger than 75 years.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2286-2294"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}